Zhuldyz Aimagambetova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhuldyz Aimagambetova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Tairkhan Dautov
University Medical Center
2 shared publications - Ainara Darbayeva
Scientific Research Institute of Radiology Named after Zh.H. Khamzabayev Astana Medical University, Astana, Republic of Kazakhstan
1 shared publication - Raushan Ibzhanovna Rakhimzhanova
Astana Medical University
1 shared publication - Vitaly G. Polushkin
Intel Diagnostic
1 shared publication Ж. М. Аймагамбетова
НАО «Медицинский университет Астана
1 shared publicationР. И. Рахимжанова
НАО «Медицинский университет Астана
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 107 (3) , 190-199
Combined Positron Emission Tomography and Computed Tomography Using 68Ga-FAPI in the Diagnosis of Gastric Cancer Metastases and Evaluation of Antitumor Treatment Effectiveness
Gastric cancer (GC) remains one of the leading causes of cancer-related morbidity and mortality worldwide, ranking fifth in morbidity and fourth in mortality, with 1,089,103 new cases and 768,793 deaths recorded globally in 2022. This corresponds to a high mortality-to-incidence ratio of approximately 0.70, underscoring its aggressive clinical behavior and late-stage presentation. In Kazakhstan, the burden of GC is particularly significant: it ranks among the five most prevalent malignancies in the country, accounting for 11.43% of all oncological deaths and emphasizing its major contribution to national cancer mortality. Positron emission tomography/computed tomography (PET/CT) has become a cornerstone in oncologic imaging due to its dual ability to assess both metabolic activity and anatomical details. However, 18 F-fluorodeoxyglucose ( 18 F-FDG), the most commonly used radiotracer, has well-recognized limitations in GC. Low 18 F-FDG uptake is noted in mucinous, signet-ring cell, poorly differentiated tumors, and inflammation. These factors reduce its sensitivity and diagnostic accuracy. In contrast, fibroblast activation protein inhibitor 68 Ga-FAPI enables superior tumor-to-background contrast and improve visualization of lesions with low glucose metabolism. Rapid blood clearance and high FAP expression in GC further enhance detection of lymphatic, peritoneal, and distant metastases. The aim of this literature review was to provide a comprehensive evaluation of 68 Ga-FAPI PET/CT in early diagnosis, staging, and treatment monitoring of GC, as well as analyse its efficacy compared to standar d 18 F-FDG PET/CT.
- 29 October 2026
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 107 (3) , 190-199
Open AccessCombined Positron Emission Tomography and Computed Tomography Using 68Ga-FAPI in the Diagnosis of Gastric Cancer Metastases and Evaluation of Antitumor Treatment Effectiveness
Gastric cancer (GC) remains one of the leading causes of cancer-related morbidity and mortality worldwide, ranking fifth in morbidity and fourth in mortality, with 1,089,103 new cases and 768,793 deaths recorded globally in 2022. This corresponds to a high mortality-to-incidence ratio of approximately 0.70, underscoring its aggressive clinical behavior and late-stage presentation. In Kazakhstan, the burden of GC is particularly significant: it ranks among the five most prevalent malignancies in the country, accounting for 11.43% of all oncological deaths and emphasizing its major contribution to national cancer mortality. Positron emission tomography/computed tomography (PET/CT) has become a cornerstone in oncologic imaging due to its dual ability to assess both metabolic activity and anatomical details. However, 18 F-fluorodeoxyglucose ( 18 F-FDG), the most commonly used radiotracer, has well-recognized limitations in GC. Low 18 F-FDG uptake is noted in mucinous, signet-ring cell, poorly differentiated tumors, and inflammation. These factors reduce its sensitivity and diagnostic accuracy. In contrast, fibroblast activation protein inhibitor 68 Ga-FAPI enables superior tumor-to-background contrast and improve visualization of lesions with low glucose metabolism. Rapid blood clearance and high FAP expression in GC further enhance detection of lymphatic, peritoneal, and distant metastases. The aim of this literature review was to provide a comprehensive evaluation of 68 Ga-FAPI PET/CT in early diagnosis, staging, and treatment monitoring of GC, as well as analyse its efficacy compared to standar d 18 F-FDG PET/CT.
- Open Access
- 1 January 2026
- Published by XMLink in Korean Journal of Radiology
- Vol. 27 (2) , 85-90
Access and Reimbursement for Artificial Intelligence in Radiology: A Central Asian Perspective
Dautov T, et al. Korean J Radiol. 2026 Jan;27:e9. https://doi.org/10.3348/kjr.2025.1638
- 1 January 2026
- Published by XMLink in Korean Journal of Radiology
- Vol. 27 (2) , 85-90
Open AccessAccess and Reimbursement for Artificial Intelligence in Radiology: A Central Asian Perspective
Dautov T, et al. Korean J Radiol. 2026 Jan;27:e9. https://doi.org/10.3348/kjr.2025.1638